India immune oncology drugs market analysis | Coherent Market Insights - PowerPoint PPT Presentation

About This Presentation

India immune oncology drugs market analysis | Coherent Market Insights


Read here the latest updates on the India immune-oncology drugs market analysis published by the CMI team. – PowerPoint PPT presentation

Number of Views:54


Transcript and Presenter's Notes

Title: India immune oncology drugs market analysis | Coherent Market Insights

Coherent Marketing Insights
  • Market Research Business Consulting Services
  • https//
  • Covid-19 Impact Tracker

  • India Immune-Oncology Drugs Market, By Drug Type
    (Immune Checkpoint Inhibitors, Monoclonal
    Antibodies, and Cancer Vaccines) and By Cancer
    Type (Lung Cancer, Blood Cancer, Breast Cancer,
    Ovarian Cancer, Cervical Cancer, Colorectal
    Cancer, Stomach Cancer, Head Neck Cancer, and
    Others) - Size, Share, Outlook, and Opportunity
    Analysis, 2018 2026

  • Immuno-Oncology refers to the use of bodys
    natural defenses to fight disease. It works by
    stimulating the immune system instead of fighting
    the tumors, avoiding disturbance in functionality
    of healthy cells. Immuno-oncology drugs
    facilitates long-term response against cancer by
    providing long-lasting memory to the immune
    system. Immuno-Oncology drugs works against a
    wide variety of cancers, which include non-small
    cell lung cancer, acute myeloid leukemia,
    lymphoma, multiple myeloma, breast cancer, and
    others. Immuno-oncology uses different types of
    cell-based immune therapies such as monoclonal
    antibodies, immune checkpoint inhibitors,
    cytokine-based immunotherapy, cancer vaccines,
    and other therapies. Commercially available
    immune-oncology therapies include Iplimumab,
    Nivolumab, Rituximab, Blinatumomab, Proleukin,
    Gardasil, and Kymriah.

  • Market Dynamics
  • Increasing prevalence of cancer in India is
    expected to drive India Immuno-Oncology Drugs
    market growth. For instance, according to
    National Cancer Registry Programme (NCRP), India,
    one woman dies of cervical cancer every 8 minutes
    in India. For every 2 women newly diagnosed with
    breast cancer, one woman dies of it in India.
    Furthermore, as many as 2,500 persons die every
    day due to tobacco-related diseases in India.
    Tobacco (smoked and smokeless) use accounted for
    around 317,928 deaths in men and women in 2018.
  • However, factors such as high-cost associated
    with immuno-oncology therapies makes it
    unaffordable for population in the low and
    middle-income class, to opt for these therapies,
    thus restraining growth of the market. For
    instance, Keytruda (Pembrolizumab), a monoclonal
    antibody for the treatment of various types of
    cancer costs around US 2,250 for a vial of 50
    mg. Moreover, according to the World Health
    Organization (WHO), in February 2018, around 70
    of deaths from cancer occur in low and
    middle-income countries. This can be attributed
    to high-prices of oncology therapies, which
    cannot be afforded by patients with low incomes.

  • Key features of the study
  • This report provides in-depth analysis of the
    India immuno-oncology drugs market, market size
    (US Mn), and Compound Annual Growth Rate (CAGR
    ()) for the forecast period 2018 2026,
    considering 2017 as the base year
  • It elucidates potential revenue opportunity
    across different segments and explains attractive
    investment proposition matrix for this market
  • This study also provides key insights about
    market drivers, restraints, opportunities, new
    product launches or approval, market trends,
    regional outlook, and competitive strategies
    adopted by leading players
  • It profiles key players in the India
    immuno-oncology drugs market based on the
    following parameters company overview,
    financial performance, product portfolio,
    geographical presence, distribution strategies,
    key developments, and strategies
  • Key players covered as a part of this study
    include Amgen, Inc., F. Hoffmann-La Roche AG,
    Intas Pharmaceuticals Ltd., AstraZeneca plc,
    Mylan N.V., Dr. Reddy's Laboratories, Bristol -
    Myers Squibb, Merck Co., Inc.,
    BIOCAD-Biotechnology company, Reliance Life
    Sciences, Biocon Limited and Hetero Drugs
  • Insights from this report would allow marketers
    and management authorities of companies to make
    informed decision with respect to their future
    product launch, governmental initiatives,
    technological up-gradation, market expansion, and
    marketing tactics

Detailed Segmentation
  • India Immuno-Oncology Drugs Market, By Drug Type
  • Immune Checkpoint Inhibitors
  • Nivolumab (Opdivo)
  • Atezolimumab (Tecentriq)
  • Pembrolizumab (Keytruda)
  • Durvalumab (Imfinzi)
  • Monoclonal Antibodies
  • Rituximab (Rituxan)
  • Trastazumab (Herceptin)
  • Bevacizumab (Avastin)
  • Nimotuzumab (Biomab EGFR)
  • Pertuzumab (Perjeta)
  • Ado-Trastuzumab Emtansine (Kadcyla)

India Immuno-Oncology Drugs Market, By Cancer
  • Lung Cancer
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Head Neck Cancer
  • Others
  • Company Profiles
  • Amgen, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies

  • Hoffmann-La Roche AG
  • Intas Pharmaceuticals Ltd.
  • AstraZeneca plc
  • Mylan N.V.
  • Reddy's Laboratories
  • Bristol - Myers Squibb
  • Merck Co., Inc.
  • BIOCAD-Biotechnology company
  • Reliance Life Sciences
  • Biocon Limited
  • Hetero Drugs Limited

  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Referance https//

About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions. We are headquartered
    in India, having office at global financial
    capital in the U.S. Our client base includes
    players from across all business verticals in
    over 150 countries worldwide.
  • What We ProvideCustomized Market Research
    AnalysisIndustry Analysis ServicesBusiness
    Consulting ServicesLong Term Engagement
    ModelCountry Specific Analysis

Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt. LTD.Coherent
    Market Insights 1001 4th Ave, 3200 Seattle, WA
    98154, U.S.Phone 1-206-701-6702
  • Email

Thank You
  • Kindly Follow CMI Social Media Profiles for the
    latest Company Updates.
  • Facebook
  • Linkedin
  • Twitter
  • https//
Write a Comment
User Comments (0)